Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brandon A Mahal

Showing results (161-170 of 214) with videos related to

Pageof 22
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|April 10, 2016
Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate CancerVinayak Muralidhar, Paul J Catalano, Gally Reznor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 24, 2019
Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer TypesWilliam S Chen, Mohammed Alshalalfa, Shuang G Zhao, et al.
Urologic Oncology|July 14, 2020
Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancerDavid D Yang, Vinayak Muralidhar, Brandon A Mahal, et al.
The Journal of Urology|February 15, 2015
Incidence and Predictors of Upgrading and Up Staging among 10,000 Contemporary Patients with Low Risk Prostate CancerKathryn T Dinh, Brandon A Mahal, David R Ziehr, et al.
Prostate Cancer and Prostatic Diseases|February 23, 2022
Substantial Gleason reclassification in Black men with national comprehensive cancer network low-risk prostate cancer - A propensity score analysisShivanshu Awasthi, Brandon A Mahal, Jong Y Park, et al.
BJU International|April 8, 2015
Risk of prostate cancer mortality in men with a history of prior cancerKathryn T Dinh, Brandon A Mahal, David R Ziehr, et al.
Clinical Genitourinary Cancer|May 28, 2014
Racial disparities in prostate cancer-specific mortality in men with low-risk prostate cancerBrandon A Mahal, Ayal A Aizer, David R Ziehr, et al.
Brachytherapy|June 2, 2014
Use of a rectal spacer with low-dose-rate brachytherapy for treatment of prostate cancer in previously irradiated patients: Initial experience and short-term resultsBrandon A Mahal, David R Ziehr, Andrew S Hyatt, et al.
Cancer|January 7, 2020
Genomic and clinical characterization of stromal infiltration markers in prostate cancerBrandon A Mahal, Mohammed Alshalalfa, Shuang G Zhao, et al.
Nature Structural & Molecular Biology|November 7, 2022
Endocrine resistance and breast cancer plasticity are controlled by CoRESTLiliana Garcia-Martinez, Andrew M Adams, Ho Lam Chan, et al.
Pageof 22

Showing results (161-170 of 214) with videos related to

Sort By:
Pageof 22
Journal of the National Comprehensive Cancer Network : JNCCN|April 10, 2016
Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate CancerVinayak Muralidhar, Paul J Catalano, Gally Reznor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 24, 2019
Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer TypesWilliam S Chen, Mohammed Alshalalfa, Shuang G Zhao, et al.
Urologic Oncology|July 14, 2020
Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancerDavid D Yang, Vinayak Muralidhar, Brandon A Mahal, et al.
The Journal of Urology|February 15, 2015
Incidence and Predictors of Upgrading and Up Staging among 10,000 Contemporary Patients with Low Risk Prostate CancerKathryn T Dinh, Brandon A Mahal, David R Ziehr, et al.
Prostate Cancer and Prostatic Diseases|February 23, 2022
Substantial Gleason reclassification in Black men with national comprehensive cancer network low-risk prostate cancer - A propensity score analysisShivanshu Awasthi, Brandon A Mahal, Jong Y Park, et al.
BJU International|April 8, 2015
Risk of prostate cancer mortality in men with a history of prior cancerKathryn T Dinh, Brandon A Mahal, David R Ziehr, et al.
Clinical Genitourinary Cancer|May 28, 2014
Racial disparities in prostate cancer-specific mortality in men with low-risk prostate cancerBrandon A Mahal, Ayal A Aizer, David R Ziehr, et al.
Brachytherapy|June 2, 2014
Use of a rectal spacer with low-dose-rate brachytherapy for treatment of prostate cancer in previously irradiated patients: Initial experience and short-term resultsBrandon A Mahal, David R Ziehr, Andrew S Hyatt, et al.
Cancer|January 7, 2020
Genomic and clinical characterization of stromal infiltration markers in prostate cancerBrandon A Mahal, Mohammed Alshalalfa, Shuang G Zhao, et al.
Nature Structural & Molecular Biology|November 7, 2022
Endocrine resistance and breast cancer plasticity are controlled by CoRESTLiliana Garcia-Martinez, Andrew M Adams, Ho Lam Chan, et al.
Pageof 22